Provided by Tiger Trade Technology Pte. Ltd.

Nektar Therapeutics

67.38
+0.74001.11%
Post-market: 67.380.00000.00%17:21 EDT
Volume:985.91K
Turnover:65.87M
Market Cap:2.30B
PE:-10.42
High:67.65
Open:67.00
Low:65.85
Close:66.64
52wk High:109.00
52wk Low:33.40
Shares:34.14M
Float Shares:28.53M
Volume Ratio:1.02
T/O Rate:3.46%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-6.4680
EPS(LYR):-9.7254
ROE:-35.75%
ROA:-12.54%
PB:2.55
PE(LYR):-6.93

Loading ...

Nektar Therapeutics - 29% and 31% of Patients Achieve Salt Score ≤20 From Week 36 to Week 52

THOMSON REUTERS
·
Apr 20

Nektar Therapeutics - Rezpegaldesleukin to Advance Into Late-Stage Development for Alopecia Areata

THOMSON REUTERS
·
Apr 20

52-Week Topline Results From 16-Week Blinded Treatment Extension of Rezolve-Aa Demonstrate Deepening of Responses in Severe-to-Very-Severe Alopecia Areata With Rezpegaldesleukin

THOMSON REUTERS
·
Apr 20

Nektar Therapeutics - Favorable Safety Profile Maintained Throughout 52 Weeks

THOMSON REUTERS
·
Apr 20

Nektar Therapeutics - 94% of Patients Completed Treatment Extension With Clinically Meaningful Hair Growth

THOMSON REUTERS
·
Apr 20

NASDAQ TRADE HALT HALT NEWS PENDING AT 07:25 AM

Reuters
·
Apr 20

Why Nektar Therapeutics (NKTR) Is Up 5.5% After 52-Week REZOLVE-AA Rezpegaldesleukin Data Release And What's Next

Simply Wall St.
·
Apr 20

Nektar to present 52-week REZOLVE-AA Phase 2b rezpegaldesleukin topline results April 20

Reuters
·
Apr 20

Nektar to Hold Conference Call to Discuss 52-Week Topline Results From the 16-Week Extension Treatment Period for Its Rezolve-Aa Phase 2B Study of Rezpegaldesleukin in Alopecia Areata on April 20, 2026

THOMSON REUTERS
·
Apr 20

A Look At Nektar Therapeutics (NKTR) Valuation After Rezpegaldesleukin Trial Progress And Litigation Concerns

Simply Wall St.
·
Apr 10

Nektar Therapeutics (NKTR) Receives a Buy from Citi

TIPRANKS
·
Apr 07

Do Rezpegaldesleukin Lawsuits Reframe Nektar Therapeutics' (NKTR) Core Risk Narrative Around Trial Integrity?

Simply Wall St.
·
Apr 05

Nektar Therapeutics Faces Investor Lawsuit Over Alleged Clinical Trial Enrollment Failures and Stock Decline

TIPRANKS
·
Apr 03

Nektar announces data from Phase 2b Rezolve-AD, Rezolve-AA studies

TIPRANKS
·
Mar 29

Nektar plans Phase 3 ZENITH-AD program after rezpegaldesleukin Phase 2b results

Reuters
·
Mar 29

Nektar Therapeutics Faces Investor Lawsuit Over Alleged Clinical Trial Enrollment Failures and Misleading Disclosures

TIPRANKS
·
Mar 25

Nektar Therapeutics Initiated at Neutral by Wedbush

Dow Jones
·
Mar 24

Nektar initiated with a Neutral at Wedbush

TIPRANKS
·
Mar 24

Wedbush Initiates Nektar Therapeutics at Neutral With $70 Price Target

MT Newswires Live
·
Mar 24

A Look At Nektar Therapeutics (NKTR) Valuation As Rezpegaldesleukin Data Heads To Major Dermatology Meeting

Simply Wall St.
·
Mar 24